Entering text into the input field will update the search result below

BioAtla sinks 47% after early results for lead candidate in solid tumor

Jan. 10, 2023 12:32 PM ETBioAtla, Inc. (BCAB) StockBMYBy: Dulan Lokuwithana, SA News Editor

Economic Recession and Market Crash Concept

mphillips007

Oncology-focused biotech BioAtla, Inc. (NASDAQ:BCAB) lost ~47% to reach the lowest level in over five months after the company shared interim results from two ongoing Phase 2 studies for its lead candidate BA3011 in patients with solid tumors.

One trial

Recommended For You

More Trending News

About BCAB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BCAB--
BioAtla, Inc.